Darunavir/Ritonavir with Rifampicin may be hepatotoxic

Darunavir/ritonavir administered with rifampicin causes hepatotoxicities in people living with HIV, according to results of a study led by researchers at the department of medicine, the Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa) and the Desmond Tutu HIV Centre at the University of Cape Town. Darunavir/ritonavir-based antiretroviral therapy (ART) is better tolerated and has a higher genetic barrier to resistance compared with second-line lopinavir/ritonavir-based ART for treatment of HIV.

Include in home page features rotation
Subscribe to rifampicin